Skip to main content
  • Policy
    Get Involved
    Join BIOAction
    View Advocacy Toolkit
    Patient Advocacy
    Human Health
    Cost and Value of Biopharmaceuticals
    Antimicrobial Resistance
    Vaccines & Biodefense
    Drug Development & Review
    International
    Global Markets & Trade
    Multilateral Organizations
    Intellectual Property
    All Policy
    Patient Advocacy

    Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access.

  • Member
    Membership Options
    Become a BIO Member
    Member Directory
    Have a Voice
    Membership Eligibility
    Member Toolkit
    Benefits By Sector
    member health
    Human Health
    member startups
    Startups
    member non R&D
    Non-R&D Companies
    Member Savings
    BBS-Programs-vwr
    VWR, Part of Avantor
    75% off Lab Supplies
    Save with BIO
    Save with BIO
  • News & Insights
    Latest biotech news
    Popular blogs
    Events
    Policy
    BIO Statements
    Press Releases
    Letters, Testimony & Comments
    Amicus Briefs
    BIO Reports
    Industry Analysis Reports
    Biotech Jobs
    Economic Development Best Practices
    BIO Briefly
    Issue Briefs
    BIO.News
    I am BIO Podcast
    All News & Insights

    Sign up for the BIO.News Newsletter >

  • Events
    Event Portfolio
    Business Development
    Health
    International
    Professional Development
    Members Only
    All Events
    BIO International Convention

    June 22-25, 2026 | San Diego, CA

    Learn More
    BIO Asia-Taiwan
    BIO Europe

    November 3-5, 2025
    Vienna, Austria

    BIO Investor Forum
    Partnering @JPM Week

    January 12-15, 2026
    San Francisco, CA

    BIO Patient & Health Advocacy Summit
    BIO Investment & Growth Summit

    March 2-3, 2026
    Miami, FL

    BIO Webinars

    Explore the webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s membership services.

  • About
    About Us
    Learn about our priorities
    BIO Leadership
    Meet BIO's Senior Leadership and Board of Directors
    Biotech Basics
    Read about biotechnology
    Industry Recognition
    Get to know the outstanding people and companies BIO supports
    Careers @ BIO
    Explore job openings with BIO today
    Diversity & Inclusion >

    Our tools and initiatives on workforce development, diversity and inclusion are designed to advance a more globally competitive industry.

  • Resource Hub
    Latest Resources
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Content Hub
    Biotech News (BIO.News)
    BIO.News Newsletter
    I am BIO Podcast
    BIO Advocacy Toolkit
    Resources Hub
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Webinars
    BIO Microsites
    Clinical Trials: The Power of Participation
    Covid Vaccine Facts
  • Search Results
    Previously Searched
Logo
Logo
Home
Search
  • Policy
    Human HealthPatient AdvocacyInternationalIntellectual PropertyAll Policies
  • Member
    Become a BIO MemberBenefits By Sector
    Human HealthStartupsNon-R&D Companies
    Member DirectoryHave a VoiceMembership EligibilitySavings
  • News & Insights
    Press ReleasesBio.News BlogLetters, Testimony & CommentsAmicus BriefsIndustry Analysis ReportsBiotech JobsEconomic Development Best PracticesIssue BriefsBIO.NewsVideosAll News & Insights
  • Events
    BIO International ConventionBIO Asia-TaiwanAll Events
  • About
    About UsBIO LeadershipDiversity & InclusionBiotech BasicsIndustry RecognitionCareers @ BIO
  • Resource Hub
    Biotech News (BIO.News)BIO.News NewsletterI am BIO PodcastBIO Advocacy ToolkitBIO Early-Stage Resources HubBIO Professional DevelopmentBIO WebinarsClinical Trials: The Power of ParticipationCovid Vaccine Facts
Search Results
Previously Searched
Search Results
Previously Searched
3105 results found
Expand All
Apply All
3105 results found

BIO Supports State and Congressional Efforts to Reject Gratuitous Requests From Oil Industry
Share
Agriculture & Environment, Sustainable Fuels  •  Press Release  •  May 9, 2020
Washington, D.C. (May 8, 2020) – The Biotechnology Innovation Organization (BIO) today released the following statement in support of the Governors' Biofuels Coalition letter urging EPA to reject unjustifiable Renewable Fuel Standard (RFS) waivers: “We thank Governors Walz and Noem and the Governors' Biofuels Coalition for opposing this unjustified request,” said Stephanie Batchelor, Vice President of BIO’s Industrial and Environmental Section. “Unfortunately, this gratuitous effort by the oil industry to use the economic pain Americans are facing to circumvent their long-standing obligations to increase the use of clean fuels is unsurprising given that they spent millions trying to fend off their obligations even before the pandemic. As we rebuild our economy, we must invest in more resilient technologies, cleaner fuels, and more sustainable manufacturing processes.  This starts by supporting the farmers and sustainable fuel producers in rural America.” In addition, BIO issued a statement in support of a bipartisan effort led by Senator's Tina Smith (D-MN), Joni Ernst (R-IA), Chuck Grassley (R-IA), and Debbie Stabenow (D-MI) to uphold the RFS and reject requests for RFS obligations to be waived. “It’s incredibly devious of the oil industry and its champions to use the economic pain Americans are facing right now to circumvent their obligations to increase the use of clean fuels. If EPA were to grant this waiver it would only undermine efforts to improve air quality and public health at this critical time,” said Stephanie Batchelor, Vice President of BIO’s Industrial and Environmental Section. “We applaud Senators Ernst and Smith for leading the opposition against this effort. We must build towards a resilient and cleaner future and that starts by promoting investment in low carbon fuels and supporting the farmers and sustainable fuel producers in rural America.” Learn more about BIO's position on sustainable fuels policy: …
Read More
green energy

Governor's Biofuels Coalition Letter Urges EPA to Reject RFS Waivers
Share
Agriculture & Environment, Sustainable Fuels  •  Letters, Testimony & Comments  •  May 8, 2020
Undermining the RFS at a time when rural America is struggling economically, farmers are fighting to stay in business, and the biofuels industry has been impacted by furloughs and plant closures is unconscionable. We respectfully urge you to reject this request and work with coalition governors to preserve rural jobs and protect our state economies. 
Read More

Merck on what pregnant women need to know about COVID-19
Share
Good Day BIO Newsletter  •  May 8, 2020
Major news to start the weekend: Moderna’s moving forward with Phase 2 of the clinical trial of its COVID-19 vaccine candidate.  In advance of Mother’s Day (Sunday May 10), we have an exclusive feature on how Merck is addressing maternal health needs in the midst of the COVID-19 pandemic, plus the latest on what you can expect to happen on Capitol Hill next week. Read in about 5 minutes (1100 words)—then call your mom to say thanks.
Read More

Administration’s Benefit Rule Threatens Access and Affordability of Prescription Medicines
Share
Human Health, Cost & Value of Biopharmaceuticals  •  Press Release  •  May 7, 2020
BIO’s Tom DiLenge, President of Advocacy, Law & Public Policy Division issued the following statement today after the Trump administration adopted a “Notice of Benefit and Payment Parameters for 2021” that allows health plans to block drug manufacturer discounts from helping to lower patients’ cost-sharing obligations: “This decision by the Trump administration is truly baffling. At a time when insurance companies are enjoying high profits while patients are struggling financially, the administration has adopted a rule that will increase patients’ out-of-pocket drug costs, undermine access to necessary medications, and further pad insurance company profits. This misguided approach will ultimately jeopardize the health and well-being of patients and lead to increased spending on other, more costly medical services. The American people should be focused on staying healthy and financially secure during these difficult times, but this reckless regulatory change risks both.” ###  
Read More

Senate Letter to Administration to Reject RFS Waivers
Share
Agriculture & Environment, Sustainable Fuels  •  Letters, Testimony & Comments  •  May 7, 2020
We urge you to direct the EPA to reject all calls to waive the RFS. The RFS is more important now than ever as farmers, the biofuel sector, and rural America struggle to remain operating amid the COVID-19 crisis.
Read More

"Herd" immunity
Share
Good Day BIO Newsletter  •  May 7, 2020
Today we have another must-listen episode of the I AM BIO Podcast about a fascinating company using animal biotech to save human lives. More on that, plus updates on more BIO members’ COVID-19 treatment breakthroughs and the latest news from Washington, in about 530 words, 3 and a half minutes.
Read More

A few things to know about coronavirus R&D
Share
Good Day BIO Newsletter  •  May 6, 2020
What can we expect in terms of coronavirus treatments and vaccines—and when? BIO’s Jim Greenwood and Merck’s Julie Gerberding have some insight on these questions, and how the industry’s rising to a very big challenge. We’re also looking at why you shouldn’t get TOO excited about lower levels of carbon emissions, and who’s calling Congress “a highly efficient virus spreading machine,” in just under 900 words, about 4 minutes, 22 seconds.
Read More

New online IP marketplace will foster collaboration
Share
Good Day BIO Newsletter  •  May 5, 2020
Vir and Alnylam have chosen their top pick for a COVID-19 therapeutic candidate, and they’re getting ready to start clinical trials. This is yet another great example of the industry’s unprecedented level of collaboration. Today, we've got news on a new IP platform that will facilitate this kind of collaboration, as well as how biotech can help ensure the sustainability of the world’s food supply, pandemic or not, in 770 words, just under 4 minutes.
Read More

New Online IP Marketplace Will Foster Collaboration in Race to Eradicate COVID-19
Share
Intellectual Property, Human Health  •  Press Release  •  May 4, 2020
To help in the response to the coronavirus pandemic, the U.S. Patent and Trademark Office today launched a new online platform, called “Patents 4 Partnerships,” to share patent information for various technologies to facilitate greater collaboration across industries. Tom DiLenge, President of BIO’s Advocacy, Law & Public Policy Division, issued the following statement in response: “The U.S. Patent and Trademark Office has taken an important step to support critical research collaboration during this pandemic. Our nation’s intellectual property protections provide a strong foundation for the rapid response against COVID-19, as thousands of scientists in hundreds of biopharmaceutical companies work around the clock to develop treatments and vaccines for this deadly virus. Our researchers are working together like never before, sharing knowledge and resources to accelerate R&D solutions. And all of this collaboration is possible because of the strong intellectual property system we have in place today, not in spite of it.  “To advance the discovery of life-saving medicines, the biopharmaceutical industry is committed to robust collaboration both across the industry and with public and nonprofit partners. This new online platform will help us achieve our shared goal of eradicating COVID-19 as quickly as possible.”   Learn more about some of the latest scientific advancements in the fight against COVID-19 at www.bio.org/coronavirus.  ###
Read More

Gilead’s good news
Share
Good Day BIO Newsletter  •  May 4, 2020
The Senate is back in Washington today, and we’re starting the week with a deeper dive into the good news from Gilead. But we’re also looking at the link between air pollution and COVID-19 deaths—and those who are still denying it. Here are 855 words, about 4 minutes, 15 seconds.
Read More

Pagination

  • First First page
  • Prev Previous page
  • …
  • 226
  • 227
  • 228
  • …
  • Next Next page
  • Last Last page
Biotechnology Innovation Organization
Explore BIO
Policy
Events
About
Industry Insights
Join Now
BIO PAC
For Members
Member Directory
BIO Policy Committees
Cost-Savings Program
BIO Events
BIO International Convention
BIO Partnering at JPM Week
BIO CEO & Investor Conference
BIO Investor Forum
BIO Patient Health & Advocacy Summit
BIO Intellectual Property Counsels Committee Conference
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2025 All Rights Reserved
Privacy Policy
Terms of Use
Contact BIO